Steroid sulfatase inhibitors and sulfated C19 steroids for proteotoxicity-related diseases: a patent spotlight.
Pharm Pat Anal
; 12(5): 213-218, 2023 Sep.
Article
en En
| MEDLINE
| ID: mdl-37982638
ABSTRACT
Aging and proteotoxicity go hand in hand. Inhibiting proteotoxicity has been proposed to extend lifespan. This invention describes a new strategy to limit proteotoxicity and to extend the lifespan. Loss of function of sul-2, the Caenorhabditis elegans steroid sulfatase, elevates the pool of sulfated steroid hormones, increases longevity and ameliorates protein aggregation diseases. The present invention provides a group of molecules for use in the prevention of aging-associated proteotoxicity caused by protein aggregation diseases and/or to increase the lifespan of a eukaryotic organism. These molecules are either steroid sulfatase inhibitors or sulfated C19 steroids, both of which reproduce the phenotype of sul-2 mutants. One particular representative example is STX-64. Potential applications of the claims have been demonstrated in animal models of Parkinson's disease, Huntington's disease and Alzheimer's disease.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Sulfatos
/
Esteril-Sulfatasa
Límite:
Animals
Idioma:
En
Revista:
Pharm Pat Anal
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos